Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide Effect on Lithium PK
NCT06719544Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity for Lithium, Area Under the Concentration versus Time Curve From Time Zero to Last Quantifiable Sample for Lithium and 1 more. Started Jan 2025; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06719544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719544.